Russia Pharmaceuticals and Healthcare Report Q4 2012

  • ID: 2299564
  • November 2012
  • Region: Russia
  • 95 pages
  • Business Monitor International
1 of 4


  • Company Profiles
  • Gedeon Richter
  • Krka
  • Lek (Novartis/Sandoz)
  • Pharmstandard
  • Stada AG (Stada CIS)
  • MORE

BMI View:

The Russian pharmaceutical market remains one of the most attractive in Central and Eastern Europe due its sheer size and the long-term growth potential of the Russian economy. The increased role of the state in the sector, on both the production side and as a purchaser of medicines has expanded the size of the market, although it has equally imposed more onerous regulations in what was once a fairly liberal pricing environment. Russia’s World Trade Organization (WTO) accession should drive improved intellectual property regulation and force Russian drugmakers to deal with stiffer competition from low-cost generics from China and India, as well as Eastern Europe. A key concern in the months ahead is political stability, amid widespread reports of tensions between the presidential administration and members of the government over key policies. On a broader level, the ability of the Russian government to deliver efficient investment and expand coverage will determine whether the pharmaceutical market can achieve greater than BMI’s 8.63% US dollar and 9.78 ruble compound annual growth rate for the 2011 to 2016 period. Whilst this rate outpaces most European READ MORE >

Note: Product cover images may vary from those shown
2 of 4


  • Company Profiles
  • Gedeon Richter
  • Krka
  • Lek (Novartis/Sandoz)
  • Pharmstandard
  • Stada AG (Stada CIS)
  • MORE

Executive Summary 5

SWOT Analysis 8

Russia Pharmaceuticals And Healthcare Industry SWOT 8

Russia Political SWOT 9

Russia Economic SWOT 9

Russia Business Environment SWOT 9

Pharmaceutical Risk/Reward Ratings 11
Table: CEE Pharmaceutical Risk/Reward Ratings, Q412 11

Rewards 12

Risks 12

Russia – Market Summary 14

Regulatory Regime 17

Intellectual Property Environment 21

Pricing Regime And Controls 22

Clinical Trials 28

Industry Trends And Developments 31

Industry Developments 35

Industry Forecast Scenario 37

Overall Market Forecast 37
Table: Pharmaceutical Sales Indicators 2008-2016 38

Key Growth Factors – Industry 39
Table: Healthcare Expenditure Indicators 2008-2016 40
Table: Healthcare Governmental Indicators 2008-2016 41
Table: Healthcare Private Indicators 2008-2016 41

Key Growth Factors – Macroeconomic 42
Table: Top 15 Planned Infrastructure Projects By Value 45
Table: Russia - Economic Activity 47

Prescription Drug Market Forecast 48
Table: Prescription Drug Sales Indicators 2008-2016 49

Generic Drug Market Forecast 50
Table: Generic Drug Sales Indicators 2008-2016 51

OTC Medicine Market Forecast 52
Table: OTC Medicine Sales Indicators 2008-2016 54

Pharmaceutical Trade Forecast 55
Table: Exports and Imports Indicators 2008-2016 57

Medical Device Market Forecast 58
Table: Medical Devices Sales Indicators 2008-2016 61

Key Risks To our Forecast Scenario 62

Competitive Landscape 63

Manufacturing Sector 63

Company Activity 69

Wholesale Sector 70

Retail Sector 71

Company Profiles 73

Berlin-Chemie/Menarini Pharma GmbH 73

Gedeon Richter 74

Krka 76

Lek (Novartis/Sandoz) 77

Stada AG (Stada CIS) 79

Veropharm 80

Pharmstandard 82

Demographic Outlook 85
Table: Russia's Population By Age Group, 1990-2020 ('000) 86
Table: Russia's Population By Age Group, 1990-2020 (% of total) 87
Table: Russia's Key Population Ratios, 1990-2020 88
Table: Russia's Rural And Urban Population, 1990-2020 88

Glossary 89

BMI Methodology 91

How We Generate Our Pharmaceutical Industry Forecasts 91

Pharmaceuticals Risk/Reward Ratings Methodology 92

Ratings Overview 92
Table: Pharmaceutical Business Environment Indicators 93

Weighting 94
Table: Weighting Of Components 94

Sources 94

Note: Product cover images may vary from those shown
3 of 4

Company Profiles
Berlin-Chemie/Menarini Pharma GmbH
Gedeon Richter
Lek (Novartis/Sandoz)
Stada AG (Stada CIS)

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown


  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.


If you have a more general question about our products please try our



Our Clients

  • Amneal Pharmaceuticals LLC.
  • Amgen Inc.
  • LEO Laboratories Ltd.
  • Pfizer Inc.
  • Roche Diagnostics Ltd.
  • Merck & Co., Inc.
  • Sanofi S.A.